CLARiTI

News

    About CLARiTI

    The ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI) was developed through a 2-year planning process with input from the Imaging Core Steering Committee, NIH, and all of the 37 Alzheimer’s Disease Research Centers (ADRC). Through this process it became clear that there were important scientific gaps that the centers could rapidly and uniquely fill by incorporating standardized PET and MRI protocols into each center’s research visit schedule.

    CLARiTI is a multi-site imaging observational study that will occur at the ADRC sites whose scientific and logistical success is facilitated by the well-established resources and environment that already exists nationally. CLARiTI runs on top of this infrastructure and seeks to closely collaborate and leverage established resources whenever possible. The consortium of ADRCs have the expertise and capacity to conduct this study and will work together to ensure its success and its impact on the field.

    NACC will create subcontracts with each of the clinical sites (the 37 ADRCs) to conduct the work proposed in the CLARiTI scope of work. NACC also coordinates flow of data from the sites to the various workgroup components of CLARiTI. CLARiTI will provide resources for standardized neuroimaging acquisitions by supporting acquisition costs as well as effort for faculty and staff.

    CLARiTI

    Why CLARiTI?

    Multi-etiology dementia (MED) is common but undetected in major cohort studies and clinical trials, likely slowing the discovery of new treatments. Except for the ADRCs, cohort studies intentionally restrict clinical heterogeneity to an assumed single disease. The ADRCs actively follow the largest MED cohort with a variety of critical UDS assessments including autopsy, but there is a major resource gap as imaging on this cohort is limited and ad-hoc, slowing progress. ATN imaging-a critical foundation for characterizing likely dementia etiologies—is needed on this expertly diagnosed, uniformly evaluated MED ADRD cohort where neuropathology can inform clinicopathologic correlation, mechanistic underpinnings, and strategic diagnostic and therapeutic development.

    How CLARiTI Addresses This Need

    • CLARiTI will utilize NACC infrastructure to accelerate and track MRI and PET image submissions from the ADRCs and to make additional image analysis and summary results available to AD/ADRD researchers through the NACC Data Front Door. The NACC infrastructure is being designed to integrate any new case report forms that are needed, including visual interpretations of images and neuropathology reports. This pipeline will return Amyloid and Tau quantitative values processed by SCAN alongside Amyloid status determined through a hybrid quantitative-qualitative assessment from the CLARiTI Image Interpretation Core to the ADRCs for their participants that are part of the CLARiTI study with secure protocols that are in accordance with HIPAA. Work flows for Tau status are currently being developed by the CLARiTI Image Interpretation Core and will be provided in Year 2 onward of the grant. The planned data flow infrastructure is shown in the figure below.
    • The CLARiTI Disclosure Core will provide workflows for disclosure of PET status to individual sites, which may be helpful for sites that do not yet have workflows in place. We are aware that many sites are already performing PET disclosure and will not use these disclosure workflows.
    • CLARiTI includes a Neuropathology Core and digital pathology resource that facilitates neuropath-guided image analysis; this will likely become a major resource that can be leveraged to enhance the existing NIH investment in the program (and in the 900 existing brains from ADRC donors with antemortem imaging).
    • CLARiTI will provide an unprecedented ADRC cohort of ATN data linked to extensive affiliated data on a clinically heterogenous cohort of 2000 unique participants that is available to the scientific community via NACC. This will substantially accelerate scientific discovery in the ADRC network.
    • CLARiTI will build a bridge to future uniform plasma ADRD biomarker characterization in the ADRCs: Use context validation, future cost savings, and repository for discovery.
    • The CLARiTI Inclusion Core will provide resources related to the recruitment of under-represented individuals, and will work with individual sites to bolster their recruitment goals.
    CLARiTI

    CLARiTI Data Flow Infrastructure

    Data Sharing

    CLARiTI is committed to sharing its data, images and biofluids and their derived values with qualified investigators. Indeed, a major purpose of the overall initiative and a stated goal of Aim 1 is to create and share the resource. The way that CLARiTI images and data are integrated into the overall ADRC data repository (the NACC Data Platform) and shared with Researchers everywhere is shown in the figure below.

    The National Alzheimer’s Coordinating Center (NACC) functions as the data coordinating center for CLARiTI. The overall approach is that broad consent will be obtained that authorizes sharing of the data via the NACC and SCAN/LONI repositories. The images and data and biospecimens collected on ADRC participants through CLARiTI immediately become part of, and integrated with, the national databases at NACC. In addition, copies of the images may remain local for use by the site in their local research.

    NACC Data Platform

    NACC Data Platform showcasing how CLARiTI will contribute to data collection and sharing via NACC’s Data Platform and Data Front Door.

    Administration and Funding

    A key component to CLARiTI is the funding it provides to ADRCs to support the expanded cohort and data collection proposed by CLARiTI:

    Each ADRC will receive:

    • $10,000 (+ 30% for indirect costs) for study start up
    • FTE for study coordination (+ 30% for indirect costs)
    • FTE for outreach and recruitment support (+ 30% for indirect costs) to work with ORE cores to achieve 25% participation of underrepresented groups in ATN data collection.

      NOTE: We also hope to increase brain donor enrollment in these underrepresented groups.

    • $10,000/year (+ 30% for indirect costs) site allowance for local events and to pay community boards, etc.
    • Payments for image contributions to CLARiTI

      NOTE: Image submissions cannot overlap with the 24 image submissions that will now be required as part of the P30s.

    Funding will be distributed to ADRCs by NACC via individual subawards between NACC and the 37 participating ADRCs. Please reach out to clariti@medicine.wisc.edu for a letter template to request the 30% indirect cost rate from your institution.

    Meet the Team

    CLARiTI Executive Leadership

    Sterling Johnson
    • Sterling Johnson
    • mPI
    • Administration Co-Lead
    • Sterling Johnson

    • mPI
    • Administration Co-Lead
    Sterling Johnson

    Dr. Johnson is a clinical neuropsychologist with research interests in early identification of Alzheimer's disease and related disorders. He leads the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a longitudinal cohort study of 1500+ people at varying levels of risk for sporadic Alzheimer's disease. He is the associate director and Biomarker Core leader in the Wisconsin ADRC, as well as the associate director of the Wisconsin Alzheimer's Institute. 

    Beth Mormino
    • Beth Mormino
    • mPI
    • Administration Co-Lead
    • Beth Mormino

    • mPI
    • Administration Co-Lead
    Beth Mormino
    Brad Dickerson
    • Brad Dickerson
    • mPI
    • Brad Dickerson

    • mPI
    Brad Dickerson
    Dr. Brad Dickerson is a Professor of Neurology at Harvard Medical School, and at Massachusetts General Hospital he is the Tommy Rickles Endowed Chair in Primary Progressive Aphasia Research, Director of the Frontotemporal Disorders Unit, and Leader of the Alzheimer’s Disease Research Center Imaging Core. He runs a multidisciplinary clinical and research program focused on patients with a variety of forms of Frontotemporal Lobar Degeneration and Alzheimer’s disease. His scientific focus is 1) cognitive, affective, and imaging neuroscience in the healthy adult across the lifespan; 2) technology development in neuroimaging; and 3) the translation of innovative cognitive-behavioral phenotyping and advanced imaging technology to patients with neurodegenerative disease.
    Bud Kukull
    • Bud Kukull
    • mPI
    • Site and Data Coordination Co-Lead
    • Bud Kukull

    • mPI
    • Site and Data Coordination Co-Lead
    Bud Kukull

    Dr. Kukull's research is focused on the neurodegenerative, vascular and other conditions causing dementia and cognitive impairment. These conditions include Alzheimer's disease, Parkinson's/Lewy body disease, frontotemporal lobar degeneration, and cerebrovascular disease. Since 1999, he has served as Director and PI of the National Alzheimer's Coordinating Center [U24 AG072122], an effort to collect and make available to researchers standardized, detailed clinical data from the approximately 37 NIA-funded Alzheimer Disease Centers across the United States. Dr. Kukull works closely with the leadership of the ADRCs and the National Institute on Aging to ensure that scientifically relevant and valid data are obtained and available from NACC’s database to any researcher anywhere.

    In addition to NACC work, he is an investigator with a number of other NIH grants. He is an elected Fellow of: American College of Epidemiology, American Academy of Neurology and American Association for Advancement of Science.

    Dave Wolk
    • Dave Wolk
    • mPI
    • Dave Wolk

    • mPI
    Dave Wolk

    Dr. David Wolk is Professor of Neurology, Chief of the Division of Cognitive Neurology, Director of the National Institute of Aging funded Penn Alzheimer’s Disease Research Center, and Co-Director of the Penn Institute on Aging.

    Dr. Wolk’s primary clinical interest has been in the diagnosis and care of individuals with a variety of neurodegenerative conditions. His research has focused on the cognitive neuroscience of memory decline associated with aging and Alzheimer’s Disease using techniques including behavioral testing, structural and functional MRI, and FDG and molecular PET imaging. Much of this work is also directed at examining biomarkers, including behavioral and neuroimaging, that differentiate healthy aging from the earliest transition to AD and their potential role in understanding disease mechanisms and incorporation into treatment trials. Dr. Wolk has had sustained NIH support since 2003 and has been the principal or co-investigator on numerous local, national and international studies, including therapeutic trials.

    Dr. Wolk completed his medical training at Johns Hopkins University, a Neurology residency at the University of Pennsylvania, and clinical Fellowship training in Cognitive and Behavioral Neurology at Brigham and Women’s Hospital/Harvard Medical School; where he also completed a post-doctoral research fellowship studying memory in Alzheimer’s Disease. Amongst a number of honors, he is the recipient of the American Academy of Neurology’s Norman Geschwind Prize in Behavioral Neurology.

    Gil Rabinovici
    • Gil Rabinovici
    • mPI
    • Image Reads Lead
    • Gil Rabinovici

    • mPI
    • Image Reads Lead
    Gil Rabinovici

    Dr. Gil Rabinovici holds the Edward Fein and Pearl Landrith Distinguished Professorship in Memory & Aging in the UCSF Department of Neurology. He received his BS degree from Stanford University and MD from Northwestern University Medical School. He completed neurology residency (and chief residency) at UCSF and a behavioral neurology fellowship at the UCSF Memory and Aging Center (MAC), where he cares for patients with cognitive disorders.

    Dr. Rabinovici’s research investigates how structural, functional and molecular brain imaging techniques can be used to improve diagnostic accuracy in dementia and study the biology of neurodegenerative diseases, with the goal of accelerating drug development. He is the director of the NIH-funded UCSF Alzheimer’s Disease Research Center, study chair of the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) and New IDEAS studies (~25,000 total participants), as well as co-PI on the emerging Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET), co-PI and PET Core lead of the Longitudinal Evaluation of Alzheimer’s Disease Study (LEADS) and PI on several additional national and local clinical, imaging and translational studies focused on Alzheimer’s disease and related disorders. His work is supported by the NIH, Alzheimer’s Association, American College of Radiology, Rainwater Charitable Foundation and industry partners. He has authored over 290 peer-reviewed publications, and the impact of his work is ranked in the top 1% in the field of Neuroscience.

    Dr. Rabinovici’s contributions have been recognized with numerous awards, including the 2022 Kuhl-Lassen Award from the Society for Nuclear Medicine and Molecular Imaging,  2015 Christopher Clark Award in Amyloid Imaging, the 2012 American Academy of Neurology Research Award in Geriatric Neurology and the 2010 de Leon Prize from the Alzheimer’s Association.

    Monica Rivera-Mindt
    • Monica Rivera-Mindt
    • mPI
    • Inclusion Co-Lead
    • Monica Rivera-Mindt

    • mPI
    • Inclusion Co-Lead
    Monica Rivera-Mindt
    Dr. Mónica Rivera Mindt, a board-certified neuropsychologist, is Past-President of the Hispanic Neuropsychological Society and a tenured Professor of Psychology, Latinx Studies, and African & African American Studies at Fordham University with a joint appointment in Neurology at the Icahn School of Medicine at Mount Sinai. Her multidisciplinary, community-based research portfolio as PI/MPI totals ~$200 million, and is supported by the NIH/NIA, the Alzheimer’s Association, and Genentech. She has built and sustained a culturally-informed, productive, and novel independent program of research through a team science approach and by successfully competing for extramural funding for 20+ years. Her work primarily focuses on the intersection between cultural neuroscience and health inequities in cognitive aging. Her current studies are examining genetic, cerebrovascular, and sociocultural risk and resilience factors for cognitive impairment and dementia in minoritized populations, as well as ways to increase diverse representation in cognitive aging and dementia research. At the national level, she is PI/mPI of multiple NIA-funded studies, including the - Biomarker Evaluation in Young Onset Dementia from Diverse Populations (BEYONDD; R56AG075744), the ADRC Consortium for Clarity in ADRD Research Through Imaging (CLARiTI; U01AG082350), and the Alzheimer’s Disease Neuroimaging Initiative’s (ADNI) Engagement Core (2U19AG024904-16). Locally, she also serves as Treasurer for the Harlem Community & Academic Partnership (HCAP). She has authored more than 100+ peer-reviewed publications and book chapters. In addition, she is deeply dedicated to mentoring and training the next generation of scientists to promote healthy, equitable cognitive aging. She has formally Mentored 50+ trainees over the course of her career, and has provided emergent, supportive mentoring to dozens more trainees in need of culturally-informed mentorship and support. As a bilingual (Spanish/English), Afro-Latinx/Indigenous neuroscientist, she brings a unique perspective to her research and is the recipient of several awards for her research, teaching, and contributions to the field, including the 2020 Martha Bernal Award for the Advancement of Diversity Training and Education in Clinical Psychology from the Council of University Directors of Clinical Psychology (CUDCP) and 2019 Hispanic Health Leadership Award from the National Hispanic Medical Association. She is also a Fellow of the American Psychological Association (Division 40, Society for Clinical Neuropsychology), the National Academy of Neuropsychology, and Hispanic Neuropsychological Society.
    Ozioma Okonkwo
    • Ozioma Okonkwo
    • mPI
    • Inclusion Co-Lead
    • Ozioma Okonkwo

    • mPI
    • Inclusion Co-Lead
    Ozioma Okonkwo

    Dr. Ozioma Okonkwo is a faculty member in the Division of Geriatrics and Gerontology within the Department of Medicine. He is a neuropsychologist and executive committee member at the Wisconsin Alzheimer’s Disease Research Center and the Wisconsin Registry for Alzheimer’s Prevention.

    Dr. Okonkwo is a faculty trainer on three graduate programs at the UW School of Medicine and Public Health. He also serves on two National Institutes of Health study sections; on committees at the National Academy of Neuropsychology, the American Psychological Association Division 40 and the Preclinical Alzheimer’s Disease Consortium; on the Board of Governors of the International Neuropsychological Society; and on the editorial board of the journals Brain Plasticityand Journal of Alzheimer’s Disease. He has received an Early Career Award from the National Academy of Neuropsychology and an Early Career Impact Award from the Federation of Associations in Behavioral and Brain Sciences.

    Tatiana Foroud
    • Tatiana Foroud
    • mPI
    • Tatiana Foroud

    • mPI
    Tatiana Foroud
    Nathaniel Chin
    • Nathaniel Chin
    • Disclosure Co-Lead
    • Nathaniel Chin

    • Disclosure Co-Lead
    Nathaniel Chin

    Dr. Nathaniel Chin is an associate professor in the Department of Medicine and Division of Geriatrics and Gerontology. Dr. Chin sees patients in the UW Health Memory Clinic where he also serves as the Associate Program Director. His clinical focus is on the early identification of cognitive impairment and the development of a holistic approach to care post-diagnosis. He is the medical director of the WI Alzheimer’s Disease Research Study and the Wisconsin Registry for Alzheimer’s Prevention Study. His research focuses on understanding the perceptions and implications of biomarker disclosure as well as the effect of addressing modifiable risk factors. He has created over 170 podcasts on AD research and caregiving topics under his podcast called Dementia Matters.

    Lindsay Clark
    • Lindsay Clark
    • Disclosure Co-Lead
    • Lindsay Clark

    • Disclosure Co-Lead
    Lindsay Clark

    Dr. Lindsay Clark is a faculty member in the Division of Geriatrics and Gerontology in the Department of Medicine. As a neuropsychologist specializing in geriatrics, Dr. Clark provides diagnostic assessments and treatment planning as part of the UW Sauk Prairie Outreach clinic and VA Geriatric Research Education and Clinical Center (GRECC) Connect Teledementia and Cognitive Care Clinics.

    She leads research projects to address barriers to early detection of cognitive impairment, including developing best practices for disclosure of AD biomarker results as well as investigating the feasibility, reliability, and validity of digital cognitive tools and direct-to-home televideo memory evaluations. She collaborates on large multi-site studies, including leading the Neuropsychology service within the Wisconsin Alzheimer’s Disease Research Center and serving as site PI for a national study evaluating video-based cognitive assessment.

    Analisse Rahman-Filipiak
    • Analisse Rahman-Filipiak
    • Disclosure Co-Lead
    • Analisse Rahman-Filipiak

    • Disclosure Co-Lead
    Analisse Rahman-Filipiak
    Dr. Rahman-Filipiak is a neuropsychologist and assistant professor in the Department of Psychiatry – Neuropsychology Section at the University of Michigan. She leads a laboratory in the Research Program on Cognition & Neuromodulation Based Interventions (RP-CNBI), a team of researchers focused on non-pharmacologic interventions for Alzheimer’s disease and related dementias (ADRD). Her research focuses on racial-ethnic disparities in dementia diagnosis and treatment, as well as community-informed approaches for recruitment and retention of diverse older adults in ADRD research. She currently leads two clinical trials evaluating the bioethical issues and impacts of AD biomarker disclosure. Dr. Rahman-Filipiak also leads return of results efforts at the Michigan Alzheimer’s Disease Research Center, where she has recently accepted a role to co-lead the Outreach, Recruitment, and Engagement Core.
    Sarah Biber
    • Sarah Biber
    • Administration Co-Lead, Site and Data Coordination Co-Lead
    • Sarah Biber

    • Administration Co-Lead, Site and Data Coordination Co-Lead
    Sarah Biber

    Dr. Sarah Biber is the Executive Director for the National Alzheimer’s Coordinating Center (NACC), based at the University of Washington. NACC serves as the data, communication, and collaboration hub, and centralized data repository for NIA’s National Alzheimer’s Disease Research Centers (ADRC) Program, comprised of 33 centers across the United States. NACC is home to one of the largest (48,600+ participants), oldest, and most powerful AD/ADRD datasets. Dr. Biber co-leads NACC’s scientific and strategic direction and $58 million project and grant portfolio with NACC PI and Director, Dr. Walter Kukull. Within this role, she represents NACC with national partners, spearheads national initiatives, leads development of major grant applications, leads academic and industry partnerships, and oversees NACC’s tech, operations, research, communications, and grants and finance teams. Under her leadership, NACC is modernizing data infrastructure and expanding interoperability across the national Alzheimer’s Disease and Related Dementia (ADRD) ecosystem to advance research and discovery. She has a PhD in molecular and cellular biology and extensive experience leading strategy for complex centers and programs focused on advancing research and innovation.

    Prior to joining NACC in November 2021, Dr. Biber led the Surgical Innovation Program at Oregon Health and Science University (OHSU) where she shaped and significantly expanded the department of surgery’s innovation capacity and footprint, co-developed surgical innovations, led academic and industry partnerships, and founded the OHSU Invent-a-thon. She previously served as the Assistant Director for NIH’s National Center for Data to Health (CD2H), where she was instrumental in launching the center and led operations to advance informatics innovation, data sharing, software development, and collaboration across the 50+ Clinical Translational Science Awards Program Centers. Prior to CD2H, she was Entrepreneurial Program Director at the Oregon Bioscience Incubator where she helped grow the incubator three-fold and spearheaded statewide partnerships to advance entrepreneurship and startups, served on state-wide committees, and co-founded Accelerate Biotech and Digital Health PDX.

    Dirk Keene
    • Dirk Keene
    • Neuropathology Lead
    • Dirk Keene

    • Neuropathology Lead
    Dirk Keene
    Howie Rosen
    • Howie Rosen
    • Image Analysis Co-Lead
    • Howie Rosen

    • Image Analysis Co-Lead
    Howie Rosen

    Dr. Rosen is a behavioral neurologist and holds the Dorothy Kirsten French Foundation Endowed Professorship for Parkinsonian and Other Neurodegenerative Disorders. He received his medical degree from Boston University School of Medicine, trained in internal medicine at the Albert Einstein College of Medicine in New York, and subsequently completed a neurology residency at UCSF. After residency, Dr. Rosen pursued fellowship training in brain imaging at the Washington University School of Medicine, and then returned to UCSF to join the team at the Memory and Aging Center (MAC) in 1999.

    Dr. Rosen’s primary research interest is in the effects that atypical neurodegenerative diseases, in particular frontotemporal dementia, have on the brain, especially the emotional systems. His current projects use psychophysiology and imaging to examine how these diseases affect self-awareness and to determine how imaging and other biological markers can be used to track and to anticipate how these diseases affect the brain over time. He is also the director of education and outreach for the education core at UCSF’s Alzheimer’s Disease Research Center.

    As part of the Memory and Aging Center, the Global Brain Health Institute and the UCSF Department of Neurology, he participates in the training of medical students, residents and fellows, and he participates in the evaluation of new patients in the MAC clinic as well as the continued management of care for individuals in the continuity clinic.

    Paul Thompson
    • Paul Thompson
    • Image Analysis Co-Lead
    • Paul Thompson

    • Image Analysis Co-Lead
    Paul Thompson

    Paul Thompson is a Professor in the Keck School of Medicine of USC, and associate director for the Stevens Neuroimaging & Informatics Institute at USC. His team’s research projects focus on neuroscience, mathematics, computer science, software engineering and clinical aspects of neuroimaging and brain mapping.

    The ENIGMA Consortium, led by Thompson since 2009, performs some of the largest-ever studies of the human brain, analyzing brain scans of more than 100,000 people worldwide. This collaborative group studies over 30 brain diseases in 45 countries, focusing on the interaction between brain health and genetics. ENIGMA has published some of the largest-ever neuroimaging studies of schizophrenia, major depression, bipolar disorder, epilepsy, autism spectrum disorder, and obsessive–compulsive disorder, and has discovered over 500 genomic loci that affect brain aging and development.

    In 2020, Thompson launched AI4AD, a NIA-funded consortium, to develop AI tools to analyze and integrate genetic, imaging, and cognitive data relating to Alzheimer’s disease.

    In 2023, Thompson launched the India ENIGMA Initiative, a study of factors that affect brain aging and mental health in India. Dr Thompson received the 2023 Pioneer in Medicine Award from the Society for Brain Mapping and Therapeutics, and commonly lectures on clinical neuroimaging and AI methods.

    John Detre
    • John Detre
    • Advanced MRI Lead
    • John Detre

    • Advanced MRI Lead
    John Detre
    Jeff Dage
    • Jeff Dage
    • Plasma Biomarkers Lead
    • Jeff Dage

    • Plasma Biomarkers Lead
    Jeff Dage
    Dr. Jeffrey Dage is a Senior Research Professor of Neurology at Indiana University School of Medicine and primary member of the Stark Neurosciences Research Institute. He received his PhD from the University of Cincinnati in Ohio where he worked in the area of protein characterization using mass spectrometry. He has been in the pharmaceutical industry for the last 28 years and has contributed to many therapeutic discovery programs through analytical measurement of biologically relevant molecules in cell culture, preclinical models, and human clinical samples. His research at Indiana University is focused on the discovery and development of biomarkers for Alzheimer’s disease and related dementias. Over the last several years he led the discovery and development of ultrasensitive immunoassays to measure phosphorylated tau in blood for use in Alzheimer’s disease diagnosis, prognosis, and clinical trials. These blood-based biomarker assays have led to dramatic change in AD research and clinical development.
    Mike Donohue
    • Mike Donohue
    • Statistics Lead
    • Mike Donohue

    • Statistics Lead
    Mike Donohue
    Michael Donohue is Professor of Neurology at the Keck School of Medicine and Associate Director of Biostatistics at the Alzheimer’s Therapeutic Research Institute (ATRI). He received his PhD in Mathematics from the University of California, San Diego. Dr. Donohue applies novel statistical methods to data from natural history studies and clinical trials to better understand the multivariate course of markers of Alzheimer’s progression, and design innovative clinical trials to prevent or slow the progression of disease. He has studied the risk of cognitive decline associated with elevated brain amyloid in cognitively normal individuals; and helped design the first intervention in asymptomatic Alzheimer’s, the Anti-Amyloid Treatment for Asymptomatic Alzheimer’s (A4) study (in collaboration with Eli Lilly), and its primary outcome measure, the Preclinical Alzheimer Cognitive Composite.
    Tim Hohman
    • Tim Hohman
    • Data Harmonization Lead
    • Tim Hohman

    • Data Harmonization Lead
    Tim Hohman
    Dr. Timothy Hohman is an Associate Professor of Neurology, cognitive neuroscientist, and computational geneticist, whose research leverages advanced computational approaches from genomics, proteomics, and neuroscience to identify novel markers of Alzheimer's disease risk and resilience. Dr. Hohman leads the Biomarker Core for the Vanderbilt Memory and Alzheimer's Center, directs the Genomics Core for the Preclinical Alzheimer's Disease Consortium and is the contact PI for the Alzheimer's Disease Sequencing Project (ADSP) Phenotype Harmonization Consortium.
    Bill Jagust
    • Bill Jagust
    • SCAN Imaging Lead
    • Bill Jagust

    • SCAN Imaging Lead
    Bill Jagust

    CLARiTI is composed of several committees (pictured below):

    CLARiTI Committees

    CLARiTI Committees

    1. mPI leadership and NIA SO— guides overall direction
    2. External advisors (TBD)
    3. Industry Stakeholders Committee
    4. Steering committee – includes all the P30 site PIs
    5. Executive committee – manages CLARiTI operations (implementation/problem solving)
    6. Cores and Components – teams that manage the core project goals

    The CLARiTI Core and Component Teams

    Administration

    • Sterling Johnson (Co-lead)
    • Beth Mormino (Co-lead)
    • Sarah Biber (Co-lead)
    • Erin Chin – CLARiTI Program Administrator
    • Laurie Robertson – Administrative Specialist
    • Phoebe Frenette - Communications Specialist
    • Kelsey Shuda – Project Coordinator
    • Hanzhe Gao – Project Coordinator
    • TBD – Lead Regulatory Coordinator

    Inclusion

    • Monica Rivera-Mindt (Co-lead)
    • Ozioma Okonkwo (Co-lead)
    • Anne Buffington – CLARiTI Inclusion Core Program Manager

    Clinical Operations - Disclosure

    • Annalise Rahman-Filipiak(Co-lead)
    • Lindsay Clark (Co-lead)
    • Nathaniel Chin (Co-lead)
    • Neelum Aggarwal
    • Brad Dickerson
    • TBD – Study coordinator

    Clinical Operations - Visual Reads

    • Gil Rabinovici (Lead)
    • Victor Villemagne (Co-lead)

    Data Coordination and Integration - Site and Data Coordination

    • Bud Kukull (Co-lead)
    • Sarah Biber (Co-lead)
    • Brittany Hale – Project Manager
    • TBD – CLARiTi Program Manager

    Data Coordination and Integration - Data Harmonization

    • Tim Hohman (Lead)

    Data Coordination and Integration - Image Analysis

    • Paul Thompson (Co-lead)
    • Howie Rosen (Co-lead)

    Data Coordination and Integration - Statistics

    • Mike Donohue (Lead)

    SCAN Imaging

    • Bill Jagust (Lead)
    • Clifford Jack

    Advanced MRI

    • John Detre (Lead)
    • Konstantinos Arfanakis

    Neuropathology

    • C. Dirk Keene (Lead)
    • Howie Rosen

    Plasma Biomarkers

    • Jeff Dage (Lead)
    • Tatiana Foroud

    Partners

    National Alzheimer’s Coordinating Center (NACC)

    The National Alzheimer’s Coordinating Center (NACC) is home to one of the largest, oldest, and most powerful Alzheimer’s datasets, built in collaboration with more than 42 (37 current) Alzheimer’s Disease Research Centers (ADRCs) throughout the US over the past 20+ years.

    NACC will serve as the data coordination center for the project which is in keeping with NACC’s overall priority to facilitate data collection, integration, and sharing of data that advances ADRD research. All NACC data is freely available to researchers. On NACC, there is currently UDS data available on over 40K unique individuals and postmortem data available for over 6K Clinical Core participants. NACC has active collaborations with NCRAD and SCAN/LONI to bridge the extensive data on NACC with datatypes stored separately (biosamples at NCRAD, imaging data at LONI).

    NACC

    National Centralized Repository for AD (NCRAD)

    The National Centralized Repository for AD (Foroud; Indiana University) has been supporting genetics and biofluid collection in the center's program since 1990 and is a major source for biofluids nationally pertaining to ADRD. NCRAD. NCRAD has a strong relationship with each center. The blood samples collected for CLARiTI will be done with kits supplied by NCRAD, shipped to NCRAD and assayed at NCRAD. The results will be integrated into the ADRC system at NACC and also given back to the sites.

    NCRAD Logo

    Standardized Centralized Alzheimer’s & Related Dementias Neuroimaging (SCAN)

    SCAN is a U24 collaboration led by Dr. Bill Jagust (UC Berkeley) and Dr. Clifford Jack (Mayo Clinic), colleagues at UC Davis, University of Michigan, and the Laboratory for Neuroimaging (LONI) at University of Southern California to collect standardized MRI and PET data across the ADRC program. The standardized MRI and PET images obtained in CLARITi will reside at LONI. SCAN investigators will QC the PET and MRI data and conduct essential processing to make the data available to the scientific community via NACC. CLARiTI will work with raw and processed standardized images at LONI to achieve its aims including visual reads and any additional quantification in collaboration with relevant entities and investigators.

    SCAN Logo

    The ADRC Program

    The National Institute on Aging (NIA) funds 33 Alzheimer’s Disease Research Centers (ADRCs) at major medical institutions across the United States. Researchers at these Centers are working to translate research advances into improved diagnosis and care for people with Alzheimer’s disease, as well as working to find a treatment or way to prevent Alzheimer’s and other types of dementia. In addition, NIA funds 4 Exploratory ADRCs that are designed to expand and diversify research and education opportunities to new areas of the country, new populations, and new areas of science and approaches to research.

    CLARiTI will leverage the resources of the NIA-funded P30 Alzheimer’s Research Centers program, which was originally established with 6 funded centers in 1984.

    NIH Logo

    Toolkits and Resources

    Preparing to participate in CLARiTI? Please review the following resources

    FAQs

    • How can I be sure I’m on the CLARiTI contact list?

      Please email clariti@medicine.wisc.edu. Let us know your name, job title, and institution and we will get you added.

    • Will there be a single IRB?

      Yes, we are using WCG as our single IRB.

    • Will CLARiTI have materials available in other languages besides English?

      Any site can have materials translated into another language which can happen one of two ways. WCG, our single IRB contracts with an outside company that provides translation services. We would upload your documents and simply select that translation is necessary and will select a language. Alternatively, your site can provide WCG already translated documents for review, as long as they are accompanied with an official certificate of translation provided for each document.

    • If we have multiple locations under one ADRC how are we set up differently for CLARiTI?

      Our budget only includes funding for 37 ADRC’s. If your ADRC has multiple locations, you will have to allocate the funding as you see fit under one single subaward. The funding and scanning goal for CLARiTI remains unchanged. Please note, if scanning takes place at multiple locations, you may be required to have separate consent documents if any of the site specific information is different among your sites.

    • What does the funding cover?

      See administration and funding section above.

    • What about redundant procedures? If a participant has provided ADCFB blood at NCRAD, DVCID MRI at LONI or SCAN MRI (Option 1+)?

      If these are done within 12 months of CLARiTI, then they do not need to be repeated.

    • How are scans uploaded?

      Scans will be uploaded to LONI using the IDA uploader. CLARiTI will have a project parallel to SCAN and will use the same interface and same meta-data and user experience, through a separate CLARiTI dashboard.

    • Can you provide a draft letter that sites can send to their grants offices to request the 30% indirect cost rate?

      You can find the letter here.

    • Are the blood tests processed in a CLIA certified lab, so sites can potentially disclose results?

      No, not at this time.

    • Is there any consideration of accepting lesser volumes of blood to go to NCRAD?

      If blood volumes have been collected within a year of CLARiTI, we will not be requiring additional blood testing.

    Contact Us